High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study

Medicine
Ting-Ting GengMan Huang

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI) has become increasingly frequent threat recently, especially in the intensive care unit (ICU). High-dose tigecycline (TGC) regimen is proposed due to the limitation of treatment options. We investigated the efficacy and safety of high-dose TGC combination regimens for treating CRKP BSI. Furthermore, the risk factors for mortality were also determined.This was a single center retrospective cohort study conducted from 2014 to 2016. A total of 40 patients with nosocomial CRKP BSI admitted to the ICU were included; they were classified into two groups according to the treatment regimens with high-dose TGC (HD group) or not (non-HD group). In-hospital mortality rates and microbiologic responses from both groups were reviewed and compared. Besides, the survival and non-survival groups were compared to identify the risk factors of mortality.Twenty-three patients constituted the HD group (high-dosage TGC regimen was administered as 200 mg loading dose followed by 100 mg every 12 h) and 17 patients constituted the non-HD group (standard dose TGC therapy as 100 mg loading dose followed by 50 mg every 12 h and other antibiotics). The in-hospital mortality was 52...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·Gopal MuralidharanSteven Troy
Nov 1, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Gopi PatelDavid P Calfee
Aug 29, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Abraham BorerMichael Sherf
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Elizabeth A NeunerDavid van Duin
Jun 29, 2011·Future Microbiology·Matthew E FalagasPatrice Nordmann
Jul 5, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D Ben-DavidG Rahav
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson
Jul 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mario TumbarelloMatteo Bassetti
Dec 21, 2012·Expert Review of Anti-infective Therapy·George L DaikosLeonidas S Tzouvelekis
Jan 30, 2013·Diagnostic Microbiology and Infectious Disease·Gary E Stein, Timothy Babinchak
Jan 31, 2013·Intensive Care Medicine·R P DellingerUNKNOWN Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup
Dec 21, 2013·Scandinavian Journal of Infectious Diseases·B Balandin MorenoP Galdos Anuncibay
Mar 8, 2014·International Journal of Antimicrobial Agents·Matthew E FalagasGiannoula S Tansarli
Jun 3, 2014·Critical Care : the Official Journal of the Critical Care Forum·Gennaro De PascaleMassimo Antonelli
Jul 16, 2014·Scandinavian Journal of Infectious Diseases·Matthaios Papadimitriou-OlivgerisEvangelos D Anastassiou
Aug 19, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Fengcai ShenYiyu Deng
Mar 24, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F-P HuW Huang
Apr 1, 2016·Journal of Infection in Developing Countries·Yangmin HuHaibin Dai
Jan 20, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Papadimitriou-OlivgerisM Marangos
Mar 31, 2017·Annals of Clinical Microbiology and Antimicrobials·Liangfei XuXiaoling Ma

❮ Previous
Next ❯

Citations

Jun 14, 2018·Expert Opinion on Drug Safety·Matteo BassettiElda Righi
Aug 4, 2019·Expert Review of Anti-infective Therapy·Rajeev SomanHanmant Barkate
Jan 23, 2020·Journal of Clinical Medicine·Shio-Shin JeanChin-Wan Hsu
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi
Nov 2, 2019·World Journal of Clinical Cases·Wei HuaiQiang-Rong Zhai
Jul 15, 2020·Annals of Intensive Care·Gennaro De PascaleMassimo Antonelli
Nov 1, 2018·Current Opinion in Infectious Diseases·Mario TumbarelloHelen Giamarellou
Jun 28, 2019·Frontiers in Public Health·Ilias KaraiskosGaryphallia Poulakou
Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
Aug 9, 2020·Frontiers in Microbiology·Rym LalaouiJean-Marc Rolain
Aug 20, 2019·Indian Journal of Medical Microbiology·Balaji VeeraraghavanBalasubramanian Sundaram
Jan 1, 2019·Indian Journal of Medical Microbiology·Balaji VeeraraghavanBalasubramanian Sundaram

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

SPSS

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.